Individualizing Care: Management Beyond Medical Therapy.
Clin Liver Dis
; 22(3): 545-561, 2018 08.
Article
in En
| MEDLINE
| ID: mdl-30259852
ABSTRACT
The evolving research landscape, with advances in the omics technologies, availability of large-scale patient cohorts, and forthcoming availability of novel drugs in primary biliary cholangitis (PBC), is creating a unique opportunity for developing a precision medicine (PM) program. PM has potential to change the paradigm of management. Diagnostic work-up of PBC patients may include information on genetic variants and molecular signature to define a particular subtype of disease and provide an estimate of treatment response and survival. To reach this point, specific interventions, such as sequencing more genomes, creating bigger biobanks, and linking biological information to health data, are needed.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Precision Medicine
/
Liver Cirrhosis, Biliary
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Clin Liver Dis
Journal subject:
GASTROENTEROLOGIA
Year:
2018
Document type:
Article
Affiliation country:
Italia